NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”).

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end

Pharming Group N.V. presents its preliminary, unaudited financial report for the three months ended September 30, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.